- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02184442
The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B (PARTNERII B)
The PARTNER II Trial "Placement of AoRTic TraNscathetER" Valves Trial" (US) [PII B] for Inoperable Patients
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Cohort B was a 1:1 randomized, controlled study independently powered to compare transcatheter heart valve therapy with the first generation (SAPIEN™ THV) system to transcatheter heart valve therapy with the second generation (SAPIEN XT THV) system in patients who could not undergo surgery (inoperable).
Patients in the control arm of Cohort B received an Edwards SAPIEN THV with the associated delivery system while patients in the treatment arm of Cohort B received an Edwards SAPIEN XT THV with the associated delivery system.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Arkansas
-
Little Rock, Arkansas, États-Unis, 72211
- Arkansas Heart Hospital/Clinic
-
-
California
-
La Jolla, California, États-Unis, 92037
- Scripps Green Hospital
-
La Jolla, California, États-Unis, 92037
- Scripps Memorial Hospital
-
Los Angeles, California, États-Unis, 90048
- Cedars-Sinai Medical Center
-
Sacramento, California, États-Unis, 95816
- Mercy General Hospital
-
Stanford, California, États-Unis, 94305
- Stanford University Medical Center
-
-
Colorado
-
Denver, Colorado, États-Unis, 80045
- University of Colorado Hospital
-
-
District of Columbia
-
Washington, District of Columbia, États-Unis, 20010
- Washington Hospital Center (WHC)
-
-
Florida
-
Clearwater, Florida, États-Unis, 33756
- Morton Plant Hospital
-
Gainesville, Florida, États-Unis, 32610
- University of Florida, Gainesville
-
Miami, Florida, États-Unis, 33136
- University of Miami
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30308
- Emory University Hospital
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60612
- Rush University Medical Center
-
Chicago, Illinois, États-Unis, 60611
- Northwestern Hospital
-
Springfield, Illinois, États-Unis, 62701
- Prairie Education and Research Cooperative
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Indiana University Health-Methodist Hospital
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- The University of Iowa
-
-
Kentucky
-
Louisville, Kentucky, États-Unis, 40202
- University of Louisville - Jewish Hospital
-
-
Louisiana
-
New Orleans, Louisiana, États-Unis, 70121
- Ochsner Clinic Foundation
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21201
- University of Maryland Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, États-Unis, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48202
- Henry Ford Hospital
-
Royal Oak, Michigan, États-Unis, 48073
- William Beaumont Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55407
- Minneapolis Heart Institute Foundation
-
Rochester, Minnesota, États-Unis, 55905
- Mayo Clinic
-
-
Missouri
-
Kansas City, Missouri, États-Unis, 64111
- Saint Luke's Hospital of Kansas City Mid America
-
Saint Louis, Missouri, États-Unis, 63110
- Washington University - Barnes Jewish Hospital
-
-
Nebraska
-
Lincoln, Nebraska, États-Unis, 68526
- Nebraska Heart Institute
-
-
New Hampshire
-
Lebanon, New Hampshire, États-Unis, 03756
- Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Newark, New Jersey, États-Unis, 07112
- Newark Beth Israel
-
-
New York
-
Manhasset, New York, États-Unis, 11030
- North Shore University Hospital, NY
-
Mineola, New York, États-Unis, 11501
- Winthrop University Hospital
-
New York, New York, États-Unis, 10032
- Columbia University Medical Center
-
New York, New York, États-Unis, 10021
- Cornell University
-
-
North Carolina
-
Charleston, North Carolina, États-Unis, 29425
- Medical University of South Carolina Charleston
-
Greenville, North Carolina, États-Unis, 27834
- East Carolina Heart Institute at East Carolina University
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45219
- The Christ Hospital, Cincinnati
-
Cleveland, Ohio, États-Unis, 44195
- Cleveland Clinic Foundation
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73135
- Oklahoma Heart Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- University of Pennsylvania Hospital
-
York, Pennsylvania, États-Unis, 17403
- York Hospital
-
-
Tennessee
-
Memphis, Tennessee, États-Unis, 38120
- Baptist Memorial Hospital
-
-
Texas
-
Austin, Texas, États-Unis, 78756
- Austin Heart, PLLC
-
Dallas, Texas, États-Unis, 75230
- Medical City Dallas Hospital
-
Dallas, Texas, États-Unis, 75093
- The Heart Hospital Baylor Plano
-
Houston, Texas, États-Unis, 77030
- The University of Texas Health Science Center at Houston/Memorial Hermann Texas Medical Center
-
San Antonio, Texas, États-Unis, 78229-3900
- University of Texas Health Science Center at San Antonio (UTHSCSA)
-
-
Utah
-
Murray, Utah, États-Unis, 84157
- Intermountain Medical Center
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22904
- University of Virginia
-
Norfolk, Virginia, États-Unis, 23507
- Sentara Norfolk General Hospital
-
-
Washington
-
Seattle, Washington, États-Unis, 98195
- University of Washington
-
-
Wisconsin
-
Madison, Wisconsin, États-Unis, 53792
- University of Wisconsin - Madison
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria
- Patient was symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA Functional Class II or greater.
- The probability of death or serious, irreversible morbidity is greater than or equal to 50%.
- The heart team agreed (and verified in the case review process) that valve implantation would likely benefit the patient.
- The study patient or the study patient's legal representative was informed of the nature of the study, agreed to its provisions and had provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.
- The study patient agreed to comply with all required post-procedure follow-up visits including annual visits through 5 years and analysis close date visits, which was conducted as a phone follow-up.
Exclusion Criteria
- Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is non-calcified.
- Significant aortic disease, including marked tortuosity (hyperacute bend), aortic arch atheroma [especially if thick (> 5 mm), protruding or ulcerated] or narrowing (especially with calcification and surface irregularities) of the abdominal or thoracic aorta, severe "unfolding" and tortuosity of the thoracic aorta. (Transfemoral)
- Currently participating in an investigational drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
- It is known that the patient is currently enrolled in the PARTNER I Trial or was withdrawn from the PARTNER I Trial prior to endpoint analysis.
- Active bacterial endocarditis within 6 months (180 days) of procedure.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: TAVR - SAPIEN XT
TAVR (transaortic valve replacement) with SAPIEN XT
|
Inoperable operable patients requiring the transcatheter aortic heart valve replacement
|
Comparateur actif: TAVR - SAPIEN
TAVR (transaortic valve replacement) with SAPIEN is the control arm
|
Inoperable operable patients requiring the transcatheter aortic heart valve replacement
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Number of Participants With All-Cause Mortality and/or Major Stroke and/or Rehospitalization
Délai: 1 Year
|
All-Cause Mortality and/or Major Stroke and/or Rehospitalization at 1 Year
|
1 Year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
NYHA Classification - Change From Baseline
Délai: Baseline and 1 Year
|
New York Heart Association (NYHA), functional classification of heart failure based on how much a patient is limited during physical activity.
The rating ranges from I - IV, with the lowest as no limitations and the highest unable to carry on any physical activity without discomfort.
|
Baseline and 1 Year
|
Total Aortic Regurgitation - Change From Baseline
Délai: 1 Year
|
Total aortic regurgitation was assessed by the core lab as 'Grade 0' = None, 'Grade 1+' = Trace, 'Grade 2+' = Mild, 'Grade 3+' = Moderate, and 'Grade 4+' = Severe. Total regurgitation at one year was analyzed in the valve implant population. |
1 Year
|
Effective Orifice Area - Change From Baseline
Délai: 1 Year
|
1 Year
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Martin B Leon, MD, Columbia University
Publications et liens utiles
Publications générales
- Chen S, Redfors B, O'Neill BP, Clavel MA, Pibarot P, Elmariah S, Nazif T, Crowley A, Ben-Yehuda O, Finn MT, Alu MC, Vahl TP, Kodali S, Leon MB, Lindman BR. Low and elevated B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: an analysis of the PARTNER II trial and registry. Eur Heart J. 2020 Feb 21;41(8):958-969. doi: 10.1093/eurheartj/ehz892.
- Summers MR, Leon MB, Smith CR, Kodali SK, Thourani VH, Herrmann HC, Makkar RR, Pibarot P, Webb JG, Leipsic J, Alu MC, Crowley A, Hahn RT, Kapadia SR, Tuzcu EM, Svensson L, Cremer PC, Jaber WA. Prosthetic Valve Endocarditis After TAVR and SAVR: Insights From the PARTNER Trials. Circulation. 2019 Dec 10;140(24):1984-1994. doi: 10.1161/CIRCULATIONAHA.119.041399. Epub 2019 Nov 6.
- Furer A, Chen S, Redfors B, Elmariah S, Pibarot P, Herrmann HC, Hahn RT, Kodali S, Thourani VH, Douglas PS, Alu MC, Fearon WF, Passeri J, Malaisrie SC, Crowley A, McAndrew T, Genereux P, Ben-Yehuda O, Leon MB, Burkhoff D. Effect of Baseline Left Ventricular Ejection Fraction on 2-Year Outcomes After Transcatheter Aortic Valve Replacement: Analysis of the PARTNER 2 Trials. Circ Heart Fail. 2019 Aug;12(8):e005809. doi: 10.1161/CIRCHEARTFAILURE.118.005809. Epub 2019 Aug 1.
- Genereux P, Pibarot P, Redfors B, Bax JJ, Zhao Y, Makkar RR, Kapadia S, Thourani VH, Mack MJ, Nazif TM, Lindman BR, Babaliaros V, Vincent F, Russo M, McCabe JM, Gillam LD, Alu MC, Hahn RT, Webb JG, Leon MB, Cohen DJ. Evolution and Prognostic Impact of Cardiac Damage After Aortic Valve Replacement. J Am Coll Cardiol. 2022 Aug 23;80(8):783-800. doi: 10.1016/j.jacc.2022.05.006. Epub 2022 May 17.
- Shahim B, Redfors B, Lindman BR, Chen S, Dahlen T, Nazif T, Kapadia S, Gertz ZM, Crowley AC, Li D, Thourani VH, Kodali SK, Zajarias A, Babaliaros VC, Guyton RA, Elmariah S, Herrmann HC, Cohen DJ, Mack MJ, Smith CR, Leon MB, George I. Neutrophil-to-Lymphocyte Ratios in Patients Undergoing Aortic Valve Replacement: The PARTNER Trials and Registries. J Am Heart Assoc. 2022 Jun 7;11(11):e024091. doi: 10.1161/JAHA.121.024091. Epub 2022 Jun 3.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2010-12-PIIB
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur TAVR Implantation with SAPIEN XT
-
Claret MedicalComplétéSténose calcifiée symptomatique sévère de la valve aortique nativeÉtats-Unis, Allemagne
-
Edwards LifesciencesComplétéSténose aortique sévère symptomatiqueÉtats-Unis, Canada
-
Edwards LifesciencesComplétéSténose valvulaire aortiqueJapon
-
Institut für Pharmakologie und Präventive MedizinEstimate, GmbHComplétéDysfonctionnement de la valve pulmonaireBelgique, Canada, Suisse
-
Edwards LifesciencesActif, ne recrute pasMaladies cardiaques | Maladies cardiovasculaires | Anomalies congénitales | Malformations cardiaques congénitales | Insuffisance valvulaire pulmonaire | Sténose valvulaire pulmonaireÉtats-Unis
-
LMU KlinikumComplétéSténose valvulaire aortiqueAllemagne
-
Edwards LifesciencesComplétéSténose valvulaire aortiqueRoyaume-Uni, Allemagne, France, L'Autriche
-
Edwards LifesciencesComplété
-
University of PadovaEdwards Lifesciences; Azienda Ospedaliera di Padova; Ospedale San Bortolo di...SuspenduSténose valvulaire aortiqueItalie
-
Edwards LifesciencesComplétéMaladie de la valve aortiqueRoyaume-Uni, France, Allemagne, Italie, Canada